Jump Financial LLC purchased a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 123,707 shares of the company's stock, valued at approximately $1,530,000. Jump Financial LLC owned approximately 0.08% of Wave Life Sciences as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in WVE. KBC Group NV acquired a new position in Wave Life Sciences during the fourth quarter worth about $67,000. Summit Investment Advisors Inc. lifted its stake in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after purchasing an additional 2,308 shares in the last quarter. Westwood Wealth Management acquired a new position in shares of Wave Life Sciences during the 4th quarter worth approximately $124,000. Raymond James Financial Inc. purchased a new stake in shares of Wave Life Sciences in the fourth quarter valued at approximately $157,000. Finally, Victory Capital Management Inc. grew its position in shares of Wave Life Sciences by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 14,546 shares of the company's stock valued at $180,000 after purchasing an additional 2,073 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on WVE shares. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Wedbush started coverage on shares of Wave Life Sciences in a research note on Tuesday, April 8th. They set an "outperform" rating and a $18.00 target price on the stock. Finally, StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $22.18.
Check Out Our Latest Stock Report on WVE
Insider Activity at Wave Life Sciences
In other news, Director Christian O. Henry sold 10,500 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the sale, the chief executive officer now owns 338,351 shares of the company's stock, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by insiders.
Wave Life Sciences Trading Down 3.4 %
Shares of Wave Life Sciences stock traded down $0.23 during trading on Friday, reaching $6.56. The company's stock had a trading volume of 227,044 shares, compared to its average volume of 1,205,529. The company has a 50-day moving average price of $8.57 and a two-hundred day moving average price of $11.50. Wave Life Sciences Ltd. has a fifty-two week low of $4.25 and a fifty-two week high of $16.74. The firm has a market cap of $1.01 billion, a PE ratio of -5.93 and a beta of -0.93.
Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. On average, analysts predict that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.
Wave Life Sciences Profile
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Further Reading
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
